Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and beta cell dysfunction: a new concept in the pathogenesis of obesity-associated type 2 diabetes mellitus by Maassen, J. A. et al.
FOR DEBATE
Fatty acid-induced mitochondrial uncoupling in adipocytes
as a key protective factor against insulin resistance and beta
cell dysfunction: a new concept in the pathogenesis
of obesity-associated type 2 diabetes mellitus
J. A. Maassen & J. A. Romijn & R. J. Heine
Received: 20 December 2006 /Accepted: 6 June 2007 /Published online: 22 August 2007
# Springer-Verlag 2007
Abstract Type 2 diabetes is associated with excessive food
intake and a sedentary lifestyle. Local inflammation of white
adipose tissue induces cytokine-mediated insulin resistance
of adipocytes. This results in enhanced lipolysis within these
cells. The fatty acids that are released into the cytosol can be
removed by mitochondrial β-oxidation. The flux through
this pathway is normally limited by the rate of ADP supply,
which in turn is determined by the metabolic activity of the
adipocyte. It is expected that the latter does not adapt to an
increased rate of lipolysis. We propose that elevated fatty
acid concentrations in the cytosol of adipocytes induce
mitochondrial uncoupling and thereby allow mitochondria
to remove much larger amounts of fatty acids. By this,
release of fatty acids out of adipocytes into the circulation is
prevented. When the rate offatty acid release into the cytosol
exceeds the β-oxidation capacity, cytosolic fatty acid con-
centrations increase and induce mitochondrial toxicity. This
results in a decrease in β-oxidation capacity and the entry
of fatty acids into the circulation. Unless these released
fatty acids are removed by mitochondrial oxidation in
active muscles, these fatty acids result in ectopic triacyl-
glycerol deposits, induction of insulin resistance, beta cell
damage and diabetes. Thiazolidinediones improve mito-
chondrial function within adipocytes and may in this way
alleviate the burden imposed by the excessive fat accumu-
lation associated with the metabolic syndrome. Thus, the
number and activity of mitochondria within adipocytes
contribute to the threshold at which fatty acids are released
into the circulation, leading to insulin resistance and type 2
diabetes.
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Abbreviations
FAD flavin adenine dinucleotide
HAART highly active antiretroviral therapy
MIDD maternally inherited diabetes and deafness
mt mitochondrial
Introduction
Type 2 diabetes mellitus is generally associated with an
enhanced energy intake and too little physical exercise.
Also genetic factors determine the susceptibility to develop
this disease. Whole-body insulin resistance and a state of
low grade inflammation are early marker of the disease
process [1]. Subsequently, hyperglycaemia develops due to
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Leiden, The Netherlandsan accelerated decline in beta cell function [2–4]. Type 2
diabetesmellitusisoftenaccompaniedbyotherco-morbidities
such as hypertension and dyslipidaemia. Together, they con-
stitute the metabolic syndrome [2].
Here we present the concept that removal of fatty acids
within white adipocytes by fatty acid-induced uncoupled
mitochondrial β-oxidation protects the organism against
fatty acid leakage out of adipocytes, thereby preventing
fatty acid-induced insulin resistance in liver and muscle and
lipotoxicity in pancreatic beta cells. A consequence of this
concept is that mitochondrial dysfunction in adipocytes,
either inherited or acquired, makes the organism more prone
to develop insulin resistance and type 2 diabetes.
Mitochondria and fatty acids
One of the main functions of mitochondria, in addition to
producing ATP, is to remove fatty acids by β-oxidation. In
this way, mitochondria are able to remove NEFA and to
protect the organism against fatty acid-induced insulin
resistance and pancreatic beta cell lipotoxicity. β-Oxidation
can take place in all cell types relevant for glucose homeo-
stasis, including muscle, liver and adipocytes. During this
process, fatty acids are oxidised in the mitochondrial matrix
by NAD
+ and flavin adenine dinucleotide (FAD), yielding
acetyl coenzyme A, which is further degraded to CO2 by
the citric acid cycle. The resulting NADH and FADH2 need
to be recycled into NAD
+ and FAD by the respiratory chain
so that additional fatty acid molecules can be oxidised. This
requires a supply of ADP, which is converted into ATP by
respiratory chain activity. The rate of conversion of ATP
back into ADP, which is determined by the metabolic
activity of the cell, determines the rate at which fatty acids
can be removed by mitochondrial activity. If the capacity
of the cell to oxidise fatty acids is to be enhanced, ATP
needs to be reconverted into ADP at an increased rate. This
occurs during exercise in contracting muscle. The resulting
enhanced rate of ADP generation provides a major addition-
al sink for the oxidation of fatty acids within the body. Only
when mitochondria are in the uncoupled state can regen-
eration of NAD
+ and FAD occur without the conversion
of ATP into ADP. The released energy is then converted
into heat. Uncoupling is a physiological adaptation process,
normally regulated by specific proteins [5]. It is remarkable
that, like uncoupling proteins, fatty acids are capable of
inducing mitochondrial uncoupling, especially when their
concentrations exceed the binding capacity of fatty acid
binding proteins [6–8]. This implies that when unbound
fatty acids are present in the cytosol of cells, mitochondria
become less efficient at ATP production and generate more
heat during the oxidation of NADH and FADH2 derived
from food.
Mitochondrial uncoupling in adipocytes by fatty acids
may protect the organism against fatty acid-induced
insulin resistance and lipotoxicity
White adipocytes contain large amounts of mitochondria
in their tiny cytosolic compartment [9, 10]. There is no
obvious reason why these cells need such a large capacity
to produce ATP. We propose that, when uncoupled by fatty
acids, these mitochondria prevent the release of fatty acids
out of the adipocytes when the antilipolytic action of insulin
is attenuated.
Evidence is accumulating that inflammation of adipose
tissue is an early step in the pathogenesis of type 2 diabetes.
The combination of excessive food intake with a sedentary
lifestyle results in the formation of large adipocytes over-
loaded with triacylglycerols. Through as yet unknownmech-
anisms the adipose tissue becomes inflamed and infiltrated
by leucocytes. This leads to the release of inflammatory
cytokines such as TNF-α [11–14], a potent inducer of
insulin resistance in adipocytes which also induces lipoly-
sis. As a result, fatty acids are released out of the large
triacylglycerol pool [15]. We propose that, initially, a part
of these fatty acids are removed inside adipocytes by
partially uncoupled mitochondrial β-oxidation. In doing so,
these mitochondria create a threshold for fatty acid release
into the circulation, which would otherwise trigger the
development of whole-body insulin resistance and pancre-
atic beta cell lipotoxicity, the latter expected to occur when
the body cannot utilise these released fatty acids as fuel, for
example, in response to high food intake and little physical
exercise. Our proposed mechanism is outlined in Fig. 1.
When low amounts of fatty acids are released out of the
triacylglycerol pool in insulin-resistant adipocytes, these
fatty acids can be removed by coupled β-oxidation. The
rate of fatty acid removal by this pathway is determined by
the rate of ADP regeneration within adipocytes, which is
likely to be a more or less constant factor, merely determined
by cellular metabolism and not affected by variations in the
lipolytic rate. We propose that, when the rate of fatty acid
release exceeds the rate of fatty acid removal by coupled β-
oxidation, the increase in cytosolic concentrations of fatty
acids not bound to binding proteins (unbound) induces a
partial uncoupling of the mitochondria. Uncoupling by fatty
acids has been shown in multiple in vitro experiments [5–8,
16]. Evidence of uncoupling in vivo is provided by a study
in which exposure of heart muscle to fatty acids resulted in a
decrease in ATP production and a concomitant increase in
oxygen consumption [17]. When uncoupled, the mitochon-
dria are able to remove much larger quantities of fatty acids
through generation of heat. The degree of uncoupling
increases in with further elevations in fatty acid concentra-
tion, thus generating more heat. This represents a dynamic
adaptation of the efficiency of the mitochondrion, which is
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If, however, the rate of fatty acid release exceeds the
maximum clearance rate, fatty acids may reach concentra-
tions that are toxic to the mitochondrion [18]. At this point
β-oxidation capacity collapses and fatty acids are released
out of adipocytes and redistributed over other tissues in the
body. These ectopic triacylglycerol deposits are associated
with the development of insulin resistance in muscle and
liver and lipotoxicity in pancreatic beta cells [19]. At this
stage of the disease process physical exercise will, by virtue
of the generation of large amounts of ADP in muscle tissue,
protect against lipotoxicity and the development of insulin
resistance. This is because the muscle switches to β-
oxidation to regenerate ATP when fatty acids reach a
concentration sufficient to make the muscle resistant to
insulin-stimulated glucose uptake [20, 21].
Discussion
In our model for the development of obesity-induced whole-
body insulin resistance and beta cell damage leading to
type 2 diabetes, we propose a key role for fatty acid re-
moval by adipose tissue mitochondria. The disease process,
as outlined in Fig. 2, is initiated by the development of
cytokine-induced adipose tissue insulin resistance [11–15]
and results in the release of fatty acids into the cytosol of
the adipocytes. Further increases in cytosolic fatty acids
induce mitochondrial dysfunction [18], decreasing the rate
of β-oxidation, augmenting the fatty acid concentration,
leading to their release into the circulation. These fatty acids
are responsible for the development of insulin resistance in
liver and muscle and lipotoxicity in pancreatic beta cells.
Fatty acids do not appear to induce insulin resistance in
adipocytes [22], which otherwise would create a positive
feedback loop whereby the release of fatty acids induces
additional insulin resistance and further promotes the
release of fatty acids.
Is there any evidence to support our model? Several
studies have shown that in adipose tissue from obese animal
models and humans, mitochondrial (mt) DNA copy number
and expression of mitochondrial genes is decreased [23, 24].
In the diabetic state, mitochondrial β-oxidation of fatty
acids was found to be attenuated. In addition, mitochondria
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Fig. 1 Consequences of fatty acid release from the adipocyte
triacylglycerol pool. In insulin-sensitive adipocytes, fatty acid concen-
trations are kept low by insulin-induced antilipolytic action, re-
esterification of fatty acids and mitochondrial β-oxidation. TNF-α
induces insulin resistance and lipolysis. At low cytosolic concentrations
of unbound fatty acids, the flux through mitochondrial β-oxidation is
limited by the rate of ADP generation by cellular metabolism. At
intermediate concentrations of unbound fatty acids, uncoupling of
mitochondria is induced leading to continuous oxidation of fatty acids,
independent of ADP supply. This process generates heat and keeps
cytosolic fatty acid concentrations low. When the rate of fatty acid
release from the triacylglycerol pool exceeds the rate of fatty acid
removal, high cytosolic concentrations of unbound fatty acids develop,
which induce mitochondrial damage [18]. This results in a decline in
the capacity to remove fatty acids and the release of large amounts of
fatty acids into the circulation. Unless these are removed by muscle
activity they form ectopic triacylglycerol deposits and induce whole-
body insulin resistance and beta cell damage. Dotted arrows indicate
consequences; continuous arrows, fluxes
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the concept of mitochondrial dysfunction in adipose tissue
in states of obesity and type 2 diabetes.
Furthermore, intake of high-fat food by healthy persons
rapidly increases the basal metabolic rate. This increase is
blunted in obese individuals, whereas obese individuals
exhibit an increased thermogenesis. These observations are
suggestive for a rapid effect of ingested fatty acids on
thermogenesis by mitochondrial uncoupling. The data also
suggest that, in obese individuals, mitochondria are already
uncoupled or damaged and less responsive to further fatty
acid-induced uncoupling [25].
In vitro studies have shown that fatty acid-induced
uncoupling of the mitochondrial respiratory chain depends
on the chemical nature of these fatty acids. Unsaturated
fatty acids, such as oleic acid, are better uncouplers than
saturated fatty acids [8]. This could imply that the inclusion
of saturated fatty acids in the diet makes mitochondria less
prone to uncoupling, resulting in the earlier release of fatty
acids, i.e. at a lower fatty acid level.
A further implication of our model is that a decline in
mitochondrial function in adipocytes reduces the ability of
these cells to store triacylglycerol. Inadvertently released
fatty acids out of the triacylglycerol pool enter the cir-
culation and are redistributed in other tissues. This occurs,
for example, in individuals starting on highly active anti-
retroviral therapy (HAART) [26–29]. The nucleoside
analogues included in HAART inhibit mtDNA polymerase
and induce a ∼30–50% reduction in mtDNA content in
adipocytes and other tissues. HAART is associated with the
redistribution of peripheral fat to the central and other
compartments and with an elevated risk of developing the
metabolic syndrome and type 2 diabetes. We see this
clinical phenotype as a result of release of fatty acids by
peripheral adipocytes, which in turn is due to a decrease in
mitochondrial capacitytoremovefatty acids. The fattyacids,
after entering the circulation, induce insulin resistance and
lipotoxicity to pancreatic beta cells and become stored as
ectopic triacylglycerol deposits.
Another example of a mitochondrial dysfunction is rep-
resented by patients carrying a 3243A>G mutation in
mtDNA.Thismutationresults inan attenuatedmitochondrial
function. Most of these patients develop the maternally
inherited diabetes and deafness (MIDD) syndrome. Remark-
ably, these patients usually have a BMI of <25 kg/m
2.
Furthermore, they exhibit ectopic triacylglycerol deposits in
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Fig. 2 Proposed sequence of events leading to the development of
hyperglycaemia during the metabolic syndrome. When adipocytes
become overloaded with triacylglycerol, low-grade inflammation
develops and inflammatory cytokines such as TNF-α induce insulin
resistance in the adipocytes. This results in an elevated state of
lipolysis. When fatty acids are inadequately removed within adipo-
cytes because of mitochondrial dysfunction (for example, induced by
fatty acids or HAART therapy, fatty acids appear in the circulation,
where they induce insulin resistance of muscle and liver and
malfunction of pancreatic beta cells. The elevated circulating fatty
acid concentrations may also uncouple mitochondria in artery wall
smooth muscle cells, thereby elevating the risk of hypertension [46].
Thiazolidinediones (TZDs) ameliorate the disease process in two
ways: (1) by creating more mitochondria in adipose cells [23, 36, 37],
thereby enhancing the capacity for oxidation of fatty acids; and (2) by
enhanced re-esterification of fatty acids [39, 40]
Diabetologia (2007) 50:2036–2041 2039multiple tissues [30–33]. This clinical picture suggests the
attenuatedstorageoftriacylglycerolinadiposetissue.Around
mid-life, these patients show a decrease in insulin secretion,
which may result from lipotoxicity to pancreatic beta cells.
Congenital lipodystrophy is another clinical example
showing that an inadequate storage of triacylglycerol in
adipocytes contributes to ectopic triacylglycerol deposits
and the development of severe whole-body insulin resis-
tance and diabetes [34].
In contrast, improved mitochondrial function specifically
inadipocytesisseeninindividualstakingthiazolidinediones.
These drugs are widely used to ameliorate whole-body
insulin resistance in patients suffering from type 2 diabetes
mellitus and the metabolic syndrome. These drugs bind to
peroxisomeproliferator-activatedreceptor-γreceptors which
are highly expressed in adipocytes and in cells from the
immune system, but low in liver and muscle [35]. These
drugs increase mitochondrial copy number and mitochon-
drial gene expression specifically in adipose tissue [23, 36,
37]. Clinically, these drugs improve storage of triacylglyc-
erol in peripheral adipocytes and ameliorate fatty acid-
related insulin resistance. Patients taking these drugs tend to
store more triacylglycerol in their adipocytes, leading to
weight gain [38]. Together, these clinical data suggest that
correct mitochondrial function is needed for adequate
storage of fatty acids as triacylglycerol in adipocytes. By
this means the organism is protected against the fatty acid-
induced development of insulin resistance and lipotoxicity
to the pancreas.
As thiazolidinediones also induce the expression of genes
involved in the neogenesis of glycerol, these drugs also
enhance the re-esterification of fatty acids [36, 39, 40]. This
also contributes to the removal of fatty acids from the cir-
culation and protects adipocyte mitochondria against fatty
acid-induced damage. Because part of the glycerol in adi-
pocytes is synthesised through pathways that are dependent
upon mitochondrial function[36], this suggests that changes
in mitochondrial function also may affect the rate of glycerol
production and thereby the rate of fatty acid esterification.
To be able to perform, uncoupled β-oxidation mitochon-
dria require the presence of sufficient amounts of oxygen.
It has been suggested that a state of hypoxia occurs in
expanding adipose tissue during the development of obesity
and that this state may contribute to the development of
the metabolic syndrome [41, 42]. Our model predicts that
hypoxia in adipocytes would lead to a reduced rate of fatty
acid removal inside these cells and to more fatty acid release
into the circulation.
The sensitivity of an individual to the development of
type 2 diabetes as a result of lifestyle is determined by
genetic factors. Multiple genetic variants that modulate the
risk of an individual for the development of diabetes have
been identified, including genetic variants related to mito-
chondrial function. A high penetrance mutation in mtDNA
has been found to be associated with the MIDD syn-
drome. This mutation predominantly affects the activity of
complex I of the respiratory chain [43]. In the same bio-
chemical pathway a mutation in the LARS2 gene, which
encodes mitochondrial leucyl-tRNA synthetase 2, also
modulates the risk for diabetes [44]. Furthermore, geneti-
cally determined changes in expression levels of compo-
nents of the mitochondrial respiratory chain have been
found to be associated with an increased risk of developing
type 2 diabetes mellitus [45].Thesegeneticfactorsarelikely
to result in a decreased capacity of the mitochondria to
remove fatty acids through uncoupled β-oxidation. Thereby,
a genetic predisposition can lower the threshold for fatty acid
release by adipocytes into the circulation and as a result
enhance the risk for type 2 diabetes.
Our model of the pathogenesis of type 2 diabetes mellitus
requires experimental verification of several points, and it
certainly does not exclude the involvement of additional
factors such as the coregulation of whole-body insulin action
and insulin secretion through adipokines and the involve-
ment of uncoupling proteins in setting the threshold for
fatty acid-induced uncoupling of mitochondria. However,
we see the way fatty acids interact with mitochondria in
the cytosol of adipocytes as a major initiating event in the
disease process leading to the metabolic syndrome and
type 2 diabetes mellitus.
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